Ispire Technology (NASDAQ: ISPR) reported Q4 FY2026 revenue of $26.7 million, up 32.5% from $20.1 million a year earlier, while GAAP basic and diluted net loss per share improved to $0.24 from $0.26. The top-line rebound did not carry through to gross profit: gross margin fell to 6.3% after inventory impairments, although the adjusted EBITDA loss narrowed to $2.3 million from $4.4 million.

Core Financial Results

Revenue increased by $6.6 million year over year and 43% sequentially. However, gross profit fell to $1.7 million from $2.5 million because inventory impairments weighed on the quarter, reducing gross margin by 6.0 percentage points.

Total operating expenses declined 11.1%, but credit loss expense remained substantial and increased by $533,000. Consequently, the GAAP net loss narrowed by only $971,000 despite the revenue growth and lower overall operating expenses.

Adjusted EBITDA is a non-GAAP measure and excludes several expenses included in Ispire’s GAAP net loss.

Credit Losses Explain the Gap Between Adjusted EBITDA and the GAAP Loss

The difference between Ispire’s $2.3 million adjusted EBITDA loss and $13.8 million GAAP net loss is important. The company’s Q4 reconciliation excludes $9.18 million of credit loss expense, $540,000 of prepaid inventory impairment, $432,000 of inventory impairment, and $736,000 of stock-based compensation, among other adjustments.

As a result, the improved adjusted EBITDA figure does not mean these costs disappeared. Credit losses increased from the prior-year quarter, while inventory-related charges also reduced gross profit. Receivables quality, inventory management, and the company’s ability to convert revenue growth into gross profit therefore remain central to assessing operating improvement.

Business and Geographic Performance

Ispire did not provide a quarterly product or geographic revenue breakdown. For the full fiscal year, revenue fell 24.7% to $96.0 million, showing that the Q4 recovery did not offset weakness earlier in the year.

Fiscal 2026 U.S. cannabis vaping hardware sales declined by $17.4 million to $15.1 million. European vaping product sales decreased by $12.7 million to $61.4 million, while Asia-Pacific sales excluding China fell by $1.4 million to $10.9 million. The U.S. cannabis and European vaping businesses accounted for most of the annual revenue contraction.

Ispire is seeking additional revenue sources through its fully operational Malaysia manufacturing facility, the rollout of its Vapor ODM platform, and its nicotine pouch joint venture with Jincheng Pharma. Its IKE Tech age-gating and G-Mesh initiatives remain at earlier commercialization stages, and the release did not disclose revenue contributions from these programs.

Profitability, Cash Flow, and the Balance Sheet

For fiscal 2026, net cash used in operating activities improved to $569,000 from $7.4 million. That improvement was much larger than the reduction in the annual GAAP net loss because the cash-flow reconciliation included $20.7 million of credit loss expense, $3.5 million of stock-based compensation, $2.8 million of inventory impairment, and a favorable $6.4 million change in accounts receivable.

Despite the improvement in operating cash use, cash and restricted cash declined by approximately $5.0 million during the fiscal year to $19.4 million. Investing activities used $3.1 million, while financing activities used $1.3 million. Cash excluding restricted cash was $19.3 million at June 30, up $1.3 million from the end of the preceding quarter.

Liquidity remains relatively tight. Working capital was $803,000, down $86,000 sequentially. Ispire also reported $47.0 million due to a related party and a stockholders’ deficit of $29.2 million at fiscal year-end.

Management Perspective

Management described Q4 as an inflection point following more than a year of restructuring and investment. It expects fiscal 2027 to be the first full year of vapor and nicotine pouch production at company-owned factories in Malaysia and plans to continue advancing its ODM, age-gating, and G-Mesh programs.

However, Ispire’s previous expectation of achieving positive cash flow in the second half of calendar 2026 is now less certain. Management attributed the change to investments in the Malaysia manufacturing facility during Q1 FY2027 and did not provide a revised date for reaching positive cash flow.

Risks Investors Need to Monitor

• Gross margin recovery: Q4 gross margin fell to 6.3% from 12.3% after inventory impairments. Continued inventory charges or unfavorable product mix could prevent revenue growth from improving profitability.
• Credit losses and receivables: Credit loss expense reached $9.18 million in Q4 and $20.7 million for the fiscal year, making customer collectability a material driver of GAAP results.
• Limited working-capital cushion: Working capital was only $803,000, while the balance sheet included a $29.2 million stockholders’ deficit and $47.0 million due to a related party.
• Uncertain cash-flow timing: Malaysia investments have made the timing of positive cash flow less certain, despite the substantial improvement in fiscal-year operating cash use.
• Commercialization execution: The Malaysia facility, Vapor ODM platform, nicotine pouch venture, age-gating technology, and G-Mesh could broaden Ispire’s revenue base, but the release did not disclose material revenue from these initiatives.

Summary

Ispire ended FY2026 with a sharp quarterly revenue recovery, lower operating expenses, and a narrower adjusted EBITDA loss. Inventory impairments and elevated credit losses nevertheless kept gross margin and GAAP profitability under pressure. The next phase depends on margin normalization, receivables quality, disciplined liquidity management, and whether the Malaysia manufacturing and ODM programs begin producing meaningful commercial results.

Find out more